|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0027540,
umls-concept:C0030705,
umls-concept:C0035647,
umls-concept:C0040223,
umls-concept:C0087111,
umls-concept:C0332293,
umls-concept:C0392747,
umls-concept:C0439659,
umls-concept:C0596244,
umls-concept:C1521761,
umls-concept:C2003941
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2009-11-10
|
|
pubmed:abstractText |
To determine the short-term and medium-term risks of cancer in patients receiving anti-tumor necrosis factor alpha (anti-TNFalpha) therapies that have proven effective in the treatment of chronic inflammatory conditions.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/adalimumab,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
pubmed-author:AsklingJohanJ,
pubmed-author:BaecklundEvaE,
pubmed-author:CösterLarsL,
pubmed-author:DackhammarChristinaC,
pubmed-author:FelteliusNilsN,
pubmed-author:ForedC MichaelCM,
pubmed-author:GeborekPierreP,
pubmed-author:GranathFredrikF,
pubmed-author:JacobssonLennart TLT,
pubmed-author:KlareskogLarsL,
pubmed-author:LindbladStaffanS,
pubmed-author:RaaschouPaulineP,
pubmed-author:Rantapää-DahlqvistSolbrittS,
pubmed-author:SaxneToreT,
pubmed-author:van VollenhovenRonald FRF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3180-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19877027-Aged,
pubmed-meshheading:19877027-Antibodies, Monoclonal,
pubmed-meshheading:19877027-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19877027-Antirheumatic Agents,
pubmed-meshheading:19877027-Arthritis, Rheumatoid,
pubmed-meshheading:19877027-Cohort Studies,
pubmed-meshheading:19877027-Dose-Response Relationship, Drug,
pubmed-meshheading:19877027-Female,
pubmed-meshheading:19877027-Humans,
pubmed-meshheading:19877027-Immunoglobulin G,
pubmed-meshheading:19877027-Incidence,
pubmed-meshheading:19877027-Male,
pubmed-meshheading:19877027-Methotrexate,
pubmed-meshheading:19877027-Middle Aged,
pubmed-meshheading:19877027-Neoplasms,
pubmed-meshheading:19877027-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:19877027-Registries,
pubmed-meshheading:19877027-Retrospective Studies,
pubmed-meshheading:19877027-Risk Factors,
pubmed-meshheading:19877027-Sweden,
pubmed-meshheading:19877027-Time Factors,
pubmed-meshheading:19877027-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
|
|
pubmed:affiliation |
Department of Medicine Solna, Karolinska University Hospital at Solna and Karolinska Institutet, Stockholm, Sweden. johan.askling@ki.se
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
